Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell... by Roberta S. Azevedo, Wei-Ying Jen, Danielle Hammond, Fadi G. Haddad, Alexis Geppner, Ghayas C. Issa, Koji Sasaki, Jayastu Senapati, Elias Jabbour, Farhad Ravandi, Hagop Kantarjian, Tapan M. Kadia

Get full text

Impact of measurable residual disease clearance kinetics in patients with AML undergoing intensive chemotherapy by Wei-Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M. Kadia, Sa A. Wang, Wei Wang, Sanam Loghavi, Naval G. Daver, Courtney D. DiNardo, Ghayas C. Issa, Hussein A. Abbas, Cedric Nasnas, Alex Bataller, Samuel Urrutia, Omer S. Karrar, Sherry Pierce, Hagop M. Kantarjian, Nicholas J. Short

Get full text

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase... by Mahesh Swaminathan, Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Navel G. Daver, Guillermo Garcia-Manero, Ghayas C. Issa, Gautam Borthakur, Farhad Ravandi, Guillermo Montalban-Bravo, Tapan M. Kadia, Yesid Alvarado, Elias J. Jabbour, Nicholas J. Short, William G. Wierda, Nitin Jain, Steven M. Kornblau, Lucia Masarova, Sherry A. Pierce, Wei Qiao, Jing Ning, Hagop Kantarjian, Marina Y. Konopleva

Get full text